BPC 157 side effects

BPC 157 is often described as "side effect free" — a claim that originates almost entirely with the peptide's Croatian developers and has not been verified in independent controlled human trials. Here is what the published safety data actually shows, the regulatory flags that matter, and the open questions on long-term risk.

What the published safety data actually shows

The starting point for any honest discussion of BPC 157 side effects is that the controlled human safety dataset is very small. The Sikirić lab and collaborators have reported BPC 157 as essentially free of toxicity in rat, mouse, and dog studies across hundreds of publications. In rodent models, the peptide has been administered at doses up to 500 μg/kg via multiple routes without producing dose-limiting toxicity or overt adverse effects. This tolerability in animals is real and consistently reported — but animal tolerability has never been a reliable predictor of human tolerability for drugs that eventually reach clinical trials.

In humans, the published safety record consists of:

• A 2015 Phase I trial in 42 healthy volunteers that was marked as completed in 2016 but whose results were never published. In clinical pharmacology, failure to publish a completed Phase I trial is treated as a significant red flag, because the default scientific expectation is that safety data from human exposure gets reported regardless of outcome.
• A retrospective case series of 12 knee osteoarthritis patients treated with intra-articular BPC 157 injections, reporting no adverse events — but without systematic safety monitoring.
• A 2024 pilot study of 12 women with interstitial cystitis treated with 10 mg BPC 157 injected into the bladder wall, reporting no adverse effects at short-term follow-up. Uncontrolled and single-center.
• A 2025 pilot study of two adults receiving intravenous infusions of 10 mg on day one and 20 mg on day two, reporting no effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers.

Combined, the peer-reviewed human safety data for BPC 157 covers fewer than 30 patients across all published studies, with no randomized controlled trials, no long-term follow-up beyond weeks, and no systematic adverse event collection. When you see statements like "BPC 157 has no known side effects," what they actually mean is "no side effects have been reported in a dataset too small to reliably detect them."

Reported BPC 157 side effects

This profile is consistent with how small peptides generally behave when administered at research doses — they tend to produce local reactions at the injection site and not much else in the short term. The absence of a GI side effect signature is notable because it differentiates BPC 157 from the other two widely-used injectable peptides in the weight loss space (semaglutide and tirzepatide), which are dominated by nausea, vomiting, and constipation.

Is BPC 157 safe? The honest answer

The question "is BPC 157 safe" is one of the most-searched BPC 157 keywords, and the honest answer splits into short-term and long-term.

Short-term: probably yes, within research dosing ranges. Across the fragmentary human data (fewer than 30 patients), the rodent data (hundreds of studies), and the 2025 IV pilot tolerating 20 mg infusions with no biomarker changes, BPC 157 does not appear to produce acute toxicity at doses far above the typical 250–500 mcg subcutaneous research protocol. Users report mild local reactions and little else.

Long-term: unknown, and this is not a rhetorical "unknown." There is no published human data beyond a few weeks of exposure. The Phase I trial that would have provided systematic short-term safety data was not published. No cohort has been followed long enough to detect delayed effects. The peptide has been in broad community use since roughly 2015–2020, which means real-world exposure data is accumulating — but systematic collection of that data through pharmacovigilance systems is not happening, because BPC 157 is not a regulated drug.

The cancer concern: why it matters and why it is unresolved

The most significant theoretical risk of BPC 157 is not inflammatory, cardiovascular, or metabolic — it is oncologic. BPC 157's primary mechanism is the promotion of angiogenesis (new blood vessel formation), and angiogenesis is one of the hallmarks of cancer growth. Tumors require vascularization to grow beyond a few millimeters in diameter and to metastasize. Drugs that promote angiogenesis are generally contraindicated in patients with active or recent cancer, and there is active research on whether angiogenesis modulators might accelerate tumor progression.

BPC 157 activates pathways — FAK-paxillin, VEGFR2, ERK1/2 — that are also implicated in cancer cell migration and metastasis. A 2024–2025 wave of research commentary has raised this as a potentially serious concern. There is no direct evidence that BPC 157 causes or promotes cancer in humans, but there is also no long-term data that would have allowed such an effect to be detected. This is the single biggest open safety question on the molecule, and it is the primary reason cautious clinicians decline to recommend BPC 157 for anti-aging or general "wellness" use, regardless of preclinical tendon repair data.

Regulatory status: why BPC 157 is banned

WADA Prohibited List (S0 — Non-Approved Substances)

The World Anti-Doping Agency added BPC 157 to its Prohibited List in 2022, placing it under category S0 — Non-Approved Substances. This category covers anything not approved by a health authority for human therapeutic use. The rationale for BPC 157's inclusion was not evidence of doping-style performance enhancement, but rather the category's catch-all logic: an unapproved drug of unknown safety that athletes were using in increasing numbers. BPC 157 is prohibited for all tested athletes at all times, in and out of competition.

FDA Category 2 bulk drug substances list

The FDA maintains lists of bulk drug substances that may be used — or specifically may not be used — in pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. BPC 157 has been placed on the Category 2 list, which identifies substances that may present significant safety risks when used in compounding. The FDA's specific concerns included immunogenicity (the potential for the body to develop antibody responses to injected peptides) and peptide impurities and characterization challenges (the difficulty of verifying the identity and purity of compounded peptide material).

The practical effect of the Category 2 designation is that licensed U.S. compounding pharmacies should not be preparing BPC 157 for patient use. Products labeled as compounded BPC 157 sold through telehealth clinics in 2024–2026 are operating outside this framework, typically by importing material from jurisdictions with different rules or by continuing to compound under older guidance pending formal FDA enforcement action.

Department of Defense Prohibited Dietary Supplement Ingredients List

BPC 157 is listed on the DoD Prohibited Dietary Supplement Ingredients List per DoDI 6130.06. Service members are prohibited from using any supplement containing BPC 157, and the DoD Operation Supplement Safety (OPSS) program has published specific guidance advising against its use.

What a reasonable risk-benefit framing looks like

Given the state of the evidence, a reasonable framing is:

• For acute orthopedic injury in otherwise healthy adults, the short-term safety profile appears favorable, the preclinical mechanism is robust, and the main open risk is long-term rather than acute. The calculus shifts based on how quickly healing matters and what alternatives exist.
• For chronic "wellness" or anti-aging use, the short-term tolerability does not compensate for the long-term uncertainty, and the angiogenesis-and-cancer question becomes proportionally more concerning the longer exposure continues.
• For anyone with a personal or recent family cancer history, the lack of data on angiogenesis-and-tumor interactions is a legitimate reason to avoid the peptide entirely until better evidence exists.
• For tested athletes, the WADA ban makes the risk calculation moot regardless of efficacy.

Nothing on this page is medical advice. The evidence is thin enough that individual medical judgment, ideally from a clinician familiar with the peptide literature, is the right venue for the actual decision.

Frequently asked questions